10.1016/j.cell.2021.08.023
10.1016/j.cell.2021.08.023 · doi-reference
10.1016/j.cell.2020.06.013
10.1016/j.cell.2020.06.013 · doi-reference
10.1016/j.cell.2019.08.052
10.1016/j.cell.2019.08.052 · doi-reference
10.1016/j.cell.2020.01.026
10.1016/j.cell.2020.01.026 · doi-reference
10.1016/j.cell.2019.03.030
10.1016/j.cell.2019.03.030 · doi-reference
10.1038/nature18003
10.1038/nature18003 · doi-reference
10.1038/s41375-021-01235-z
10.1038/s41375-021-01235-z · doi-reference
Chromatin proteomics to study epigenetics - challenges and opportunities
10.1074/mcp.r120.002208 · doi-reference
10.1021/acs.jproteome.1c00331
10.1021/acs.jproteome.1c00331 · doi-reference
Phosphoproteomics reveals therapeutic targets of esophageal squamous cell carcinoma
10.1038/s41392-021-00682-5 · doi-reference
10.1146/annurev.pharmtox.44.101802.121440
10.1146/annurev.pharmtox.44.101802.121440 · doi-reference
EGF receptor ligands
10.1016/s0014-4827(02)00105-2 · doi-reference
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry
10.1038/ncomms13404 · doi-reference
10.1038/s41587-021-01038-8
10.1038/s41587-021-01038-8 · doi-reference
Antigenic essence: upgrade of cellular cancer vaccines
10.3390/cancers13040774 · doi-reference
10.1158/1078-0432.ccr-20-3752
10.1158/1078-0432.ccr-20-3752 · doi-reference
Assays Used for Discovering Small Molecule Inhibitors of YAP Activity in Cancers
10.3390/cancers14041029 · doi-reference
10.1016/j.devcel.2019.06.003
10.1016/j.devcel.2019.06.003 · doi-reference
Post-transcriptional screen of cancer amplified genes identifies ERBB2/Her2 signaling as AU-rich mRNA stability-promoting pathway
10.1038/s41389-021-00351-w · doi-reference
Proteome stability as a key factor of genome integrity
10.3390/ijms18102036 · doi-reference
Multi-omics Characterization of Interaction-mediated Control of Human Protein Abundance levels
10.1074/mcp.ra118.001280 · doi-reference
10.1016/j.celrep.2017.08.010
10.1016/j.celrep.2017.08.010 · doi-reference
10.1016/j.cell.2020.10.044
10.1016/j.cell.2020.10.044 · doi-reference
10.1016/j.cell.2020.05.043
10.1016/j.cell.2020.05.043 · doi-reference
Proteogenomic Characterization of Human Early-Onset Gastric Cancer
10.1016/j.ccell.2018.12.003 · doi-reference
Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
10.1158/0008-5472.can-20-3454 · doi-reference
Subtype-specific secretomic characterization of pulmonary neuroendocrine tumor cells
10.1038/s41467-019-11153-5 · doi-reference
10.1002/hep.29291
10.1002/hep.29291 · doi-reference
Integrated Omics of Metastatic Colorectal Cancer
10.1016/j.ccell.2020.08.002 · doi-reference
Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging
10.1021/pr200784p · doi-reference
MALDI MS imaging as a powerful tool for investigating synovial tissue
10.3109/03009742.2011.647925 · doi-reference
Pan-cancer proteomic map of 949 human cell lines
10.1016/j.ccell.2022.06.010 · doi-reference
Functional proteomic profiling analysis in four major types of gastrointestinal cancers
10.3390/biom13040701 · doi-reference
The proteogenomic landscape of curable prostate cancer
10.1016/j.ccell.2019.02.005 · doi-reference
10.1016/j.cell.2019.10.007
10.1016/j.cell.2019.10.007 · doi-reference
10.1016/j.cell.2021.07.016
10.1016/j.cell.2021.07.016 · doi-reference
10.1016/j.cell.2020.10.036
10.1016/j.cell.2020.10.036 · doi-reference
Breast cancer quantitative proteome and proteogenomic landscape
10.1038/s41467-019-09018-y · doi-reference
10.1016/j.ccell.2018.08.004
10.1016/j.ccell.2018.08.004 · doi-reference
A proteomic landscape of diffuse-type gastric cancer
10.1038/s41467-018-03121-2 · doi-reference
